Skip to main content
Clinical Trials/NCT02485600
NCT02485600
Completed
Not Applicable

Canadian Advanced Parkinson DUODOPA-Treated Patients Observational Study Evaluating Long-Term Health Outcomes in Centers of Excellence (CADENCE)

AbbVie13 sites in 1 country88 target enrollmentOctober 19, 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Parkinson Disease (PD)
Sponsor
AbbVie
Enrollment
88
Locations
13
Primary Endpoint
Change in participant's motor symptoms
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

This is an open-label, postmarketing, observational study to document health outcomes, in Canadian patients with advanced Parkinson's disease and long-term treatment with Duodopa (levodopa/carbidopa intestinal gel).

Registry
clinicaltrials.gov
Start Date
October 19, 2015
End Date
February 26, 2020
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
AbbVie
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Diagnosed with advanced Parkinson's Disease
  • Prescribed Duodopa by his/her treating physician.

Exclusion Criteria

  • Patients who were previously treated with Duodopa.
  • Presence of other condition that, in the opinion of the treating physician, prohibits the patient from participating in the study or obscures the assessment of the treatment of advanced PD.

Outcomes

Primary Outcomes

Change in participant's motor symptoms

Time Frame: Baseline, Day 1, Month 3, Month 6, and every 6 months thereafter up to 48 months

Evaluated via the Unified Parkinson's Disease Rating Scale (UPDRS) Part II, III, V and Part IV items 33-35; items 32 \& 39 modified as per MDS-UPDRS, and the Freezing of Gait Questionnaire (FOGQ).

Change in the Parkinson's Disease Questionnaire (PDQ-39)

Time Frame: Baseline, Day 1, Month 3, and every 6 months thereafter up to 48 months

Evaluated via the Parkinson's Disease Questionnaire (PDQ-39)

Change in caregiver burden

Time Frame: Baseline, Day 1, Month 3, and every 6 months thereafter up to 48 months

Evaluated via the Zarit Care Giver Burden Questionnaire.

Change in the non-motor symptoms.

Time Frame: Baseline, Day 1, Month 3, and very 6 months thereafter up to 48 months

Evaluated via the Non-Motor symptoms Scale (NMS) and the Parkinson's Disease Sleep Scale (PDSS-2).

Change in the cognitive functions.

Time Frame: Baseline, Day 1, and every 12 months thereafter up to 48 months

Evaluated via the Montreal Cognitive Assessment (MoCa).

Change in caregiver work productivity

Time Frame: Baseline, Day 1, Month 3, and every 6 months thereafter up to 48 months

Evaluated by the Work Productivity and Activity Information Questionnaire (WPAI - care giver)

Change in the participant's Healthcare Resource Utilization

Time Frame: Baseline, Month 3, and every 6 months thereafter up to 48 months

Evaluated via the Health Care Resources Utilization Questionnaire (HCRU).

Study Sites (13)

Loading locations...

Similar Trials